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Piccolo BD, Graham JL, Stanhope KL, Fiehn O, Havel PJ,
Adams SH. Plasma amino acid and metabolite signatures tracking
diabetes progression in the UCD-T2DM rat model. Am J Physiol
Endocrinol Metab 310: E958–E969, 2016. First published April 19,
2016; doi:10.1152/ajpendo.00052.2016.—Elevations of plasma con-
centrations of branched-chain amino acids (BCAAs) are observed in
human insulin resistance and type 2 diabetes mellitus (T2DM);
however, there has been some controversy with respect to the passive
or causative nature of the BCAA phenotype. Using untargeted
metabolomics, plasma BCAA and other metabolites were assessed in
lean control Sprague-Dawley rats (LC) and temporally during diabe-
tes development in the UCD-T2DM rat model, i.e., prediabetic (PD)
and 2 wk (D2W), 3 mo (D3M), and 6 mo (D6M) post-onset of
diabetes. Plasma leucine, isoleucine, and valine concentrations were
elevated only in D6M rats compared with D2W rats (by 28, 29, and
30%, respectively). This was in contrast to decreased plasma concen-
trations of several other amino acids in D3M and/or D6M relative to
LC rats (Ala, Arg, Glu, Gln, Met, Ser, Thr, and Trp). BCAAs were
positively correlated with fasting glucose and negatively correlated
with plasma insulin, total body weight, total adipose tissue weight,
and gastrocnemius muscle weight in the D3M and D6M groups.
Multivariate analysis revealed that D3M and D6M UCD-T2DM rats
had lower concentrations of amino acids, amino acid derivatives,
1,5-anhydroglucitol, and conduritol--opoxide and higher concentra-
tions of uronic acids, pantothenic acids, aconitate, benzoic acid,
lactate, and monopalmitin-2-glyceride relative to PD and D2W UCD-
T2DM rats. The UCD-T2DM rat does not display elevated plasma
BCAA concentrations until 6 mo post-onset of diabetes. With the
acknowledgement that this is a rodent model of T2DM, the results
indicate that elevated plasma BCAA concentrations are not necessary
or sufficient to elicit an insulin resistance or T2DM onset.
branched-chain amino aicds; diabetes; University of California at
Davis Type 2 Diabetes rat model; amino acids; branched-chain amino
acids
ALTERATIONS OF BRANCHED-CHAIN AMINO ACID (BCAA) metabo-
lism and increased circulating BCAA concentrations are asso-
ciated with insulin resistance and type 2 diabetes mellitus
(T2DM), based on studies utilizing untargeted and targeted
metabolite analyses in human cohorts (11–13, 24, 29, 41, 45,
51). Furthermore, circulating concentrations of BCAAs in the
obese insulin-resistant state are correlated with indices of
insulin resistance and compromised blood glucose control (3,
13, 32), whereas fasting plasma BCAA concentrations pre-
dicted T2DM development in the Framingham Offspring Study
(45). It has since been proposed that excess BCAAs can
contribute to development of insulin resistance, at least under
conditions of high-fat feeding or elevated tissue fatty acid
availability (29). Based on the weight of published evidence,
we favor the perspective that insulin resistance and/or T2DM
lead to alterations in efficient tissue BCAA catabolism, which
contributes to increased circulating BCAA levels (2, 26) and
may promote “anaplerotic stress” (1, 13). Still, the exact
mechanism behind this association, whether causative or ca-
sual, has yet to be conclusively defined.
Metabolomics analysis has provided much evidence to allow a
global view of the metabolic landscape of T2DM as well as
identify biomarkers that differentiate T2DM and insulin resistance
conditions from otherwise healthy phenotypes. In addition to
BCAAs, several other prognostic biomarkers of insulin resistance
and/or T2DM that are currently being investigated were identified
and originally characterized using metabolomics approaches (12,
41, 45, 46). The vast majority of these studies were derived from
cross-sectional studies with heterogeneous populations that in-
clude a broad range of metabolic outcomes associated with this
disease (42). Only a few studies have assessed the circulating
metabolome longitudinally before and/or after the clinical diag-
nosis of T2DM has been established (12, 14, 45–47). This is
especially critical since the progression and development of
T2DM is not a static occurrence and can take upwards of 10 yr
(20). Thus, characterization of noninvasive biomarkers that track
specific and temporal metabolic disturbances early in the progres-
sion of T2DM is needed.
To address this issue, we have utilized the University of
California at Davis Type 2 Diabetes Mellitus (UCD-T2DM) rat
model to investigate the changes in the plasma metabolome
during the progression from prediabetes to diabetes onset and
on to a state of advanced T2DM. The UCD-T2D rat sponta-
neously develops polygenic adult-onset obesity and insulin
resistance accompanied by -cell dysfunction, leading to overt
diabetes. However, unlike most other rat models of T2DM, the
UCD-T2DM rat does not have a genetic defect in the leptin
signaling pathway (9). In addition, the UCD-T2DM rat devel-
ops diabetes with ad libitum access to a standard chow diet and
at a later age compared with other rodent models of T2DM (9).
These characteristics of the UCD-T2DM rat model more
closely resemble the pathophysiology of T2DM in humans.
Thus, this model will allow us to carefully observe the metabo-
lome during an experimentally controlled progression from
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prediabetes to newly diagnosed T2DM and to the insuli-
nopenic, later stages of fulminant T2DM, which is difficult or
impossible in a human research trial. In the current study, we
addressed two primary aims: 1) to evaluate the hypothesis that
worsening metabolic status drives BCAA changes, and not
vice-versa, by determining the temporal patterns of plasma
BCAA during the progression of insulin resistance and diabe-
tes and 2) to identify novel metabolite signatures that charac-
terize the progression of metabolic changes before and after the
onset of overt long-term diabetes.
RESEARCH DESIGN AND METHODS
Animals. All animal studies were approved by the University of
California Davis Institutional Animal Care and Use Committee. Rats
were maintained on a 14:10-h light-dark schedule with ad libitum
access to standard chow (2018 Teklad Global; Harlan Laboratories,
Indianapolis, IN). The UCD-T2DM rat model was created originally
by crossing obese Sprague-Dawley rats (Charles River Laboratories,
Wilmington, MA) prone to adult-onset obesity and insulin resistance
with Zucker diabetic fatty lean rats (ZDF-lean; Charles River Labo-
ratories). ZDF-lean rats were homozygous wild-type (/) at the
leptin receptor locus (9, 31), ensuring functional leptin receptors.
ZDF-lean rats have an autosomal recessive -cell defect, causing
impairment of -cell function (16); however, the impairment is not
sufficient to disrupt normoglycemia in the absence of obesity-induced
insulin resistance (9). In-depth details of the breeding strategy have
been described previously (9). Unlike other rodent models of T2DM,
UCD-T2DM rats are fertile and produce offspring homozygous for
the -cell defect (9). Lean Sprague-Dawley control (LC; n  7) rats
(Harlan Laboratories, Indianapolis, IN) were used for comparison.
Experimental design. Blood and tissues were collected from male
UCD-T2DM rats after a 13-h fast (1900-0800) prior to the onset of
diabetes (PD; n  8) and 2 wk (D2W; n  9), 3 mo (D3M; n  14),
and 6 mo (D6M; n  16) after the onset of diabetes. Rats were given
a 200 mg/kg ip dose of pentobarbital sodium and then exsanguinated
via cardiac puncture between ca. 0800–1100. LC, PD, D2W, and
D3M rats were age-matched at time of tissue harvest (165.5  1.3
days; means  SE). D6M rats were not age-matched at tissue harvest
due to age-related logistics; therefore, D6M rats had a similar age of
diabetes onset to D3M rats but aged 90 days longer than D3M
animals. Onset of diabetes was defined as nonfasted blood glucose
concentrations 200 mg/dl on 2 consecutive wk (9); therefore,
inclusion as PD was determined in rats that met the age requirements
and had nonfasting blood glucose concentrations  200 mg/dl.
Weekly determination of nonfasting blood glucose concentrations
were taken in the afternoon between 1300 and 1600 with a glucose
meter (LifeScan One-Touch Ultra, Milpitas, CA) from a drop of tail
blood collected using a lancet.
Body composition. Subcutaneous, mesenteric, epididymal, and ret-
roperitoneal adipose depots, gasatrocnemius muscle, and liver were
dissected and weighed immediately. Total adiposity is defined as a
summed total of subcutaneous, mesenteric, epididymal, and retroper-
itoneal depots.
Plasma samples. Blood was collected in EDTA-treated tubes from
the tail prior to pentobarbital administration and used for assessment
of plasma insulin, glucose, and triglycerides. Plasma was separated by
centrifugation and stored in a 	80°C freezer until analysis. Fasting
plasma glucose was assessed with an enzymatic colorimetric assay
(Fisher Diagnostics, Middletown, VA). Plasma insulin concentrations
were measured with a rat-specific radioimmunoassay (EMD Millipore,
Billerica, MA). Plasma triglycerides were measured with an enzymatic
colorimetric assay (L-type TG H kit; Wako Chemicals, Richmond, VA).
Plasma samples used for untargeted metabolomics of primary metabo-
lism were delivered to the West Coast Metabolomics Center at the
University of California Davis Genome Center on dry ice. In-depth
details of the analytical methods have been described previously (13).
Briefly, samples were thawed, extracted, and derivatized by silylation/
methyloximation before analysis by gas chromatography quadrupole
time-of-flight mass spectrometry. Results were processed by the Fiehn
lab metabolomics BinBase database and matched against spectrum from
the Fiehn mass spectral library of 1,200 authentic metabolite spectra,
using retention index and mass spectrum information or the NIST05
commercial library. Metabolite data provided as peak heights of quanti-
fier heights normalized to the sum intensities of all reported metabolites.
Ions lacking structural identification were assigned BinBase identification
numbers (36) and were included in all statistical analyses. All metabo-
lomics data are provided as Supplemental Material (Supplemental Ma-
terial for this article is available at the AJP-Endocrinology and Metabo-
lism web site).
Statistical analysis. All statistical analyses, figures, and tables were
conducted in R (version 3.1.2, http://www.r-project.org/). Alpha was
determined at 0.05 for all statistical tests unless alternatively specified.
Group differences among plasma nonfasting and fasting glucose,
insulin, triglycerides, total weight, adiposity measurements, gastroc-
nemius muscle, liver, and plasma amino acid and amino acid deriv-
atives were assessed with a one-way ANOVA. Measurements with a
nonnormal distribution were log transformed before ANOVA. Post
hoc analysis of group means was measured by Tukey’s honestly
significantly different test. Associations among selected variables
were assessed with Spearman’s correlations. Univariate tests were
corrected for multiple comparisons using false methods by Benjamini
and Hochberg (6).
Data preprocessing treatment for multivariate analyses. Data were
first transformed with a natural log function, and then each metabolite
was assessed for univariate outliers by Grubbs’ Test for Outliers (21)
at 
  0.01. In total, 68 measurements were identified as an outlier
and removed from analysis (0.34% of all data). Of the metabolites
with removed univariate outliers, none had 10% of their data
removed. Data were then randomly split into two-thirds and one-third
training and test sets, respectively. Centering, scaling, and imputation
of missing data (i.e., data removed during outlier identification) by
K-nearest neighbor averaging were first assessed on training data and
then applied on the training and test data sets separately using the
preProcess function from the caret package (23).
Partial least squares-discriminant analysis (PLS-DA) model devel-
opment and feature selection. PLS-DA models were constructed to
identify metabolites that discriminate LC, PD, D2W, D3M, and D6M
groups (model 1) or only UCD-T2DM rat groups (model 2). Training
data were used exclusively to develop PLS-DA models and select
metabolites that contained discriminant class information. Test data
were used only to assess PLS-DA model prediction accuracy through
prediction of test set class membership. Models, including all metab-
olites, were initially constructed using functions from the caret pack-
age (23). Variable importance measurements based on weighted sums
of the absolute regression coefficients (22, 23) were assessed on the
initial models that included all metabolites. We then used a backward
iterative selection strategy to identify metabolites that contained
important discriminant information. First, variable important mea-
surements were ordered, then a PLS-DA model was fit based on that
order, and then class discrimination was predicted in the test data and
compared with the actual class membership. Models were then fit
iteratively, with the next top feature removed (as assessed by the
variable important measurement), followed by class discrimination in
the test set. Classification rates of all models were plotted and visually
assessed to determine the point at which the classification rate re-
gressed. At that point, all metabolites that had previously been
removed were considered as metabolites with important discriminant
information and used to develop final models. Final models were then
used to predict the classification group of the remaining animals
(“test” set). Ward’s hierarchical clustering method was used to cluster
the Euclidean distances of Spearman’s correlations among featured
metabolites.
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RESULTS
Characteristics of UCD-T2DM rats during uncontrolled
progression of diabetes. Similarly to previous reports (9),
nonfasting plasma glucose was similar in PD rats compared
with LC but significantly increased as diabetes progressed (Fig.
Fig. 1. Progression of diabetes and adiposity in male University of California
at Davis Type 2 Diabetes Mellitus (UCD-T2DM) rats. Plasma nonfasting
glucose (A), fasting plasma glucose (B), fasting insulin (C), fasting free fatty
acid concentrations (D), total body weight (E), total adipose tissue weight (F),
gastrocnemius muscle weight (G), and liver weight (H) in lean control
Sprague-Dawley rats (LC; n  7) and UCD-T2DM rats before the onset
[prediabetic (PD); n 8] of diabetes and 2 wk (D2W; n 9), 3 mo (D3M; n
14), and 6 mo (D6M; n  10) post-onset. Values are means  SE. Group
differences were assessed by 1-factor ANOVA. Means without a common
letter differ significantly by Tukey’s honestly significantly different (HSD)
test. Statistical significance determined at P  0.05.
Fig. 2. Correlation among fasting insulin and total weight (A), total adipose
(B), and gastrocnemius muscle (C) in lean Sprague-Dawley controls (LC; n 
7) and UCD-T2DM rats prior to the onset of diabetes (PD; n  8) and
UCD-T2DM rats 2 wk (D2W; n  9), 3 mo (D3M; n  14), and 3 mo (D6M,
n  10) post-onset of diabetes. Total adiposity is defined as a summed total of
subcutaneous, mesenteric, epididymal, and retroperitoneal adipose depots.
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1A). Fasting plasma glucose was significantly elevated only at
D6M (Fig. 1B). Fasting insulin was greater in PD and D2W
rats compared with controls but declined in D3M and D6M
rats, consistent with insulin resistance in PD and D2W fol-
lowed by a deterioration of -cell function evident in this
model during the later stages of diabetes (Fig. 1C). No differ-
ences in fasting fatty acids were observed (Fig. 1D). UCD-
T2DM rats at all diabetic stages had greater total body weight
compared with LC animals, but D3M and D6M rats had
significantly less body weight relative to PD and D2W rats
(Fig. 1E). Similar to the observations in fasting insulin, total
adiposity was greater in PD and D2W rats compared with LC
rats but regressed in D3M and D6M to weights comparable
with LC rats (Fig. 1F). Gastrocnemius muscle weight was also
greater in PD and D2W rats relative to LC animals but also
regressed in D3M and D6M rats, with D6M rats having a
significantly lower weight compared with LC rats (Fig. 1G).
Liver weights were greater in UCD-T2DM rats compared with
LC and were lower in D3M relative to the PD, D2W, and D6M
groups (Fig. 1H). Total body weight, total adiposity, and
gastrocnemius muscle weight were strongly correlated with
fasting plasma insulin across the groups (Fig. 2).
Plasma BCAAs are increased in later stages of diabetes, in
contrast to a sharp decline in most other amino acids. We
assessed the temporal differences in BCAAs and related me-
tabolites due to the numerous reports of elevated circulating
BCAAs under conditions of insulin resistance in humans (12,
13, 29, 41, 45, 51). As depicted in Fig. 3A, concentrations of all
BCAAs were significantly greater in overnight-fasted D6M
rats compared with PD or D2W groups but were not elevated
in PD, D2W, or D3M rats relative to LC rats. Plasma abun-
dance of Leu was 28% greater in D6M rats relative to D2W
rats, whereas plasma abundances of Ile and Val were 30%
greater in D6M rats compared with PD rats, respectively.
Plasma abundances of 2-ketoisocaproate, the branched-chain
keto-acid product of leucine, were significantly lower in PD,
D3M, and D6M rats compared with the LC rats; additionally,
rats in the D3M group had lower concentrations than D2W rats
(Fig. 3B). Plasma levels of the methionine/cysteine-derived
derivative 2-hydroxybutanoic acid [a.k.a. 2-hydroxybutyrate,
implicated as a marker of increased risk for T2D risk (12, 13,
15)] were significantly greater only in rats at D2W vs. LC,
although the absolute mean concentration trended higher in the
UCD-T2D rats compared with LC controls (Fig. 3B). It was
notable, from the standpoint of a putative T2DM-predictive
biomarker, that 2-hydroxybutanoic acid correlated with fasting
glucose and insulin in PD rats (Fig. 4).
In marked contrast to the BCAAs, several gluconeogenic
and ketogenic amino acids were lower in D3M and D6M
UCD-T2DM animals compared with LC animals (Table 1).
For example, Ala, Gln, Gly, Met, Ser, and Trp were all reduced
by between 16 and 36% in D6M rats relative to LC rats. Only
Asp, Trp, and citrulline differed in PD and D2W rats compared
with LC rats; all were higher, whereas citrulline remained
higher throughout the progression of diabetes (Table 1).
Using the prediabetic UCD-T2D rats as a reference, there
were very few alterations in D2W rats, but several amino acids
were significantly altered in D3M and D6M rats (Table 2).
BCAA concentrations are only higher in D6M rats relative to
PD rats, but all other significantly altered amino acids de-
creased relative to PD concentrations. Non-BCAA amino acids
and BCAA derivatives (2-ketoisocaproic acid, Ala, Asn, Gln,
Gly, Met, Ser, Thr, Trp, and ornithine) were all decreased in
both D3M and D6M rats, whereas glutamate and lysine were
decreased only in D6M rats.
Plasma concentrations of all BCAAs are correlated to total
adiposity, fasting plasma glucose, and insulin in later but not
earlier stages of diabetes. Significant associations among all
Fig. 3. Temporal changes in plasma abundances of branched-chain amino acids and branched-chain keto acid dehydrogenase substrates in male UCD-T2DM rats.
The BCAA (A) and detected branched-chain keto acid dehydrogenase substrates (B) are shown for lean Sprague-Dawley control rats (LC; n  7) and
UCD-T2DM rats before the onset (PD; n 8) of diabetes and 2 wk (D2W; n 9), 3 mo (D3M; n 14), and 6 mo (D6M; n 10) post-onset of diabetes. Upper
and lower hinges (box) are data within the interquartile range (IQR) and are values between the 1st and 3rd quartile. The median value is represented by a solid
line. Whiskers include data based on (IQR  1.5)  upper hinge and (IQR  1.5) 	 lower hinge. , Actual data that are jittered for clarity. Units are
log-transformed quantifier ion peak heights (QIPH). Group differences assessed by 1-factor ANOVA. Means without a common letter differ significantly by
Tukey’s HSD test. Statistical significance determined at P  0.05.
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measured amino acids and non-fasting glucose, fasting glu-
cose, fasting insulin, total body weight, total adiposity, and
gastrocnemius muscle in LC, PD, D2W, and late stages of
diabetes (combined D3M and D6M) are provided in Fig. 4. No
BCAAs were correlated to these parameters in LC or PD
animals. Only fasting plasma insulin, total body weight, and
total adipose weight are significantly and negatively correlated
to Val at D2W, but all BCAAs are positively correlated with
fasting plasma glucose and negatively correlated with fasting
plasma insulin, total body weight, total adipose tissue weight,
and gastrocnemius muscle weight in the later stages of diabe-
tes. Distinct correlation patterns emerged (i.e., multiple indices
correlated with several amino acids) in PD and in the late
stages of diabetes, which were not apparent in LC and D2W
groups. Except for the correlations between fasting plasma
insulin and His in LC and PD groups, there were no similarities
in significant correlation between those two groups. A pattern
emerged in PD rats, where Cys, Gln, Glyc, His, Pro, and Ser
were all positively correlated to gastrocnemius weight and
negatively correlated with both fasting glucose and fasting
insulin or just fasting insulin alone. All of these correlations
were not observed in D2W rats, with the exception of the
correlation between Ser and gastrocnemius weight. Many of
the gluconeogenic amino acids (Asp, Glu, Gln, Gly, Ser, and
Trp) in the later stages of diabetes had opposite relationships to
indices that were correlated to BCAAs.
Metabolites discriminant of progression of diabetes. In ad-
dition to examining BCAAs and other amino acids, a second-
ary aim was to characterize the “global” metabolic profile of
diabetes progression. A total of 414 metabolites were observed
in the untargeted metabolomics analysis; 146 were annotated
metabolites based on their structural identification and 268
were unknown (i.e., metabolites that did not have full structural
identification). The unknown metabolites were assigned Bin-
Base identification numbers (36) and were included in multi-
variate statistical analyses.
We found that 68 metabolites discriminated LC, PD, D2W,
D3M, and D6M rats (model 1) based on an iterative backwards
selection strategy for the PLS-DA model. Model 1 correctly
classified 85% of the 11 rats in the test data using four latent
variable dimensions. Separation of animal group clusters along
latent variable dimensions 1 and 2 is portrayed in a PLS-DA
scores plot, in which each symbol represents an individual rat
(Fig. 5A). We then used the metabolites featured in model 1
(Fig. 5B) and constructed a heat map of the log2 fold difference
of the metabolites in UCD-T2DM rats relative to the LC rats
(Fig. 5C). Metabolites clustered within the top branch of the
dendrogram in Fig. 5C are generally higher in all UCD-T2DM
rat groups relative to LC animals, whereas metabolites in the
bottom branch were all generally lower in the UCD-T2DM rats
relative to LC rats. These metabolites correspond to the sepa-
ration of LC rats from UCD-T2DM rats along latent variable
2 in model 1 (Fig. 5A).
The two middle branches (Fig. 5C) provide more informa-
tion regarding differences between early and late stages of
diabetes and correspond to the separation of early and late
stages of diabetes along latent variable 1 from model 1 (Fig.
5A). For example, the majority of the amino acids and amino
acid derivatives are found in the lower-middle branch and have
a larger negative fold difference in D3M and D6M (relative to
Fig. 4. Spearman’s correlations among clin-
ical parameters and plasma amino acids
stratified by diabetes status in rats. Correla-
tions are indicated for lean Sprague-Dawley
controls (n  7), UCD-T2DM rats prior to
the onset of diabetes (PD; n  8), UCD-
T2DM rats 2 wk post-onset of diabetes
(D2W; n  9), and UCD-T2DM rats in the
later stages of diabetes [3 (D3M) and 6 mo
(D6M) post-onset of diabetes; n  24]. Sig-
nificant correlations are presented as colored
ellipses (P  0.05). Red ellipses positioned
in a positive orientation are positive Spear-
man’s rho correlation coefficients, and blue
ellipses positioned in a negative orientation
are negative Spearman’s rho correlation co-
efficients. Darker ellipses represent a greater
absolute rho correlation coefficient. BCAAs,
branched-chain amino acids.
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LC) rats compared PD and D2W (i.e., blue shading in later-
stage groups compared with black or orange shading in early-
stage groups). The upper-middle branch (Fig. 5C) contains
metabolites that generally have a greater log2 fold change
relative to LC in D3M and D6M rats compared with PD and
D2W, viz. they are increased in late diabetes vs. early diabetes.
These metabolites include tricarboxylic acid cycle intermedi-
ates (isocitrate, aconitate, fumarate, and malic acid), hexuronic
and glucuronic acids, stearic and palmitic acids, pantothenic
acid, benzoic acid, 2-hydroxyglutaric acid, and lactate.
Much of the variance in model 1 explains the discrimination
of LC rats from UCD-T2DM rats, raising the question of
whether some metabolites depicted in Fig. 5 reflect an animal
strain effect rather than the onset and progression of diabetes
per se. Indeed, a post hoc analysis revealed that a total of 31
metabolites differed between LC and PD (Table 3). The rela-
tively high number of metabolites statistically different be-
tween LC and PD prompted us to produce a second PLS-DA
model, including only UCD-T2DM rat groups to differentiate
prediabetic vs. diabetic groups within rat strain, and to better
understand metabolites that track diabetes progression without
the potential strain confounder (model 2). In this model, 82%
of rats in the test set were correctly classified with four latent
variables, and spatial separation of all groups was visualized
along latent variables 1 and 2 (Fig. 6A). Most annotated
metabolites in model 2 were also found in model 1, except for
1,5-anhydroglucitol, glucosamine, glycerol, cysteine, and uric
acid (Fig. 6B). Using a similar heat map, but based on the log2
fold metabolite difference of D2W, D3M, and D6M rats
relative to PD rats (Fig. 6C), we found that the majority of
metabolites explain the differences between early and later
stages of diabetes (upper and lower branches). There was also
a group of metabolites whose variance does not appear to be
explained by the early and late stages of diabetes (middle
branch). Again, plasma concentrations of amino acids and
amino acid derivatives are featured prominently in model 2 and
are lower in the later stages of diabetes (D3M and D6M)
relative to PD (Fig. 6C). Interestingly, monopalmitin-1-glyc-
eride, 1-monostearin, and stearic acid were the only lipid-
derived metabolites featured in model 2. In contrast to a high
abundance of tricarboxylic acid cycle intermediates found in
model 1, aconitate was the only one also identified in model 2
(Fig. 6B). Similarly to model 1, plasma concentrations of
hexuronic and glucuronic acid, lactate, and benzoic acid were
also identified by model 2 (Fig. 6B) and also greater in D3M
and D6M (Fig. 6C).
DISCUSSION
In this study, an untargeted metabolomics approach was
used to investigate changes of plasma BCAAs and other amino
acids during the onset and progression of diabetes in the
UCD-T2DM rat model, and in addition we identified non-
amino acid metabolites that exhibited temporal changes with
diabetes progression. We did not observe significant differ-
ences in plasma concentrations of any BCAA in PD or D2W
Table 1. Fold difference of plasma amino acids and amino acid derivatives in UCD-T2DM rats relative to lean Sprague-
Dawley controls
Parameter PD D2W D3M D6M
Branched-chain amino acids and derivative
Isoleucine 0.85 (0.7, 1.1) 0.85 (0.8, 0.9) 0.93 (0.8, 1.1) 1.10 (1.0, 1.3)
Leucine 0.95 (0.8, 1.1) 0.91 (0.8, 1.0) 1.01 (0.9, 1.2) 1.17 (1.0, 1.3)
Valine 0.92 (0.8, 1.0) 0.94 (0.9, 1.0) 0.99 (0.9, 1.1) 1.20 (1.1, 1.4)
2-KIC 0.58 (0.4, 0.8)* 0.58 (0.5, 0.8)* 0.39 (0.3, 0.5)* 0.38 (0.3, 0.5)*
Gluconeogenic amino acids
Alanine 1.18 (1.0, 1.4) 1.05 (0.9, 1.2) 0.81 (0.7, 0.9) 0.78 (0.7, 0.9)*
Asparagine 1.33 (1.2, 1.6)* 1.31 (1.1, 1.5)* 1.02 (0.9, 1.1) 0.97 (0.8, 1.2)
Aspartic acid 1.18 (1.0, 1.4) 1.18 (1.0, 1.5) 1.10 (0.9, 1.4) 0.87 (0.7, 1.3)
Cysteine 1.03 (0.8, 1.3) 1.25 (1.0, 1.6) 1.09 (0.9, 1.3) 0.77 (0.6, 1.2)
Glutamate 1.34 (1.1, 1.7) 1.32 (1.1, 1.6) 1.02 (0.9, 1.2) 0.91 (0.8, 1.1)
Glutamine 1.07 (0.9, 1.3) 1.13 (1.0, 1.3) 0.87 (0.7, 1.0) 0.74 (0.6, 0.9)*
Glycine 1.18 (1.1, 1.4) 1.09 (1.0, 1.2) 0.93 (0.8, 1.1) 0.69 (0.6, 0.8)*
Histidine 1.05 (0.8, 1.3) 1.01 (0.9, 1.1) 0.85 (0.8, 1.0) 0.80 (0.7, 0.9)
Methionine 1.02 (0.9, 1.1) 0.96 (0.9, 1.1) 0.83 (0.8, 0.9)* 0.84 (0.8, 1.0)*
Proline 2.28 (1.1, 5.7) 1.11 (0.5, 3.0) 1.56 (0.8, 4.7) 1.80 (0.8, 4.8)
Serine 1.06 (1.0, 1.2) 1.01 (0.9, 1.1) 0.72 (0.7, 0.8)* 0.64 (0.6, 0.7)*
Gluconeogenic and ketogenic amino acids
Phenylalanine 1.08 (1.0, 1.2) 1.10 (1.0, 1.2) 0.94 (0.9, 1.0) 0.96 (0.9, 1.1)
Threonine 1.37 (1.3, 1.5)* 1.30 (1.1, 1.5)* 0.82 (0.7, 1.0) 0.83 (0.7, 1.0)
Tryptophan 1.13 (1.0, 1.3) 1.16 (1.0, 1.4) 0.88 (0.7, 1.1) 0.71 (0.6, 0.8)*
Tyrosine 1.06 (0.9, 1.3) 1.22 (1.0, 1.4) 1.10 (0.9, 1.3) 1.04 (0.9, 1.2)
Other amino acids and derivatives
Lysine 1.08 (0.9, 1.3) 1.07 (1.0, 1.2) 0.90 (0.8, 1.0) 0.81 (0.7, 0.9)
Arginine  ornithine 1.02 (0.6, 1.7) 0.80 (0.5, 1.3) 0.56 (0.4, 0.9)* 0.66 (0.4, 1.0)
Citrulline 1.18 (0.9, 1.4) 1.34 (1.1, 1.6)* 1.33 (1.1, 1.6)* 1.32 (1.1, 1.5)*
Ornithine 1.02 (0.7, 1.6) 0.84 (0.6, 1.3) 0.62 (0.4, 0.9)* 0.70 (0.5, 1.1)
2-HB 1.07 (0.9, 1.3) 1.32 (1.0, 1.7)* 1.11 (0.9, 1.4) 1.12 (0.9, 1.4)
Data are mean fold difference [95% confidence interval (CI)] of University of California at Davis Type 2 Diabetes Mellitus (UCD-T2DM) rats prior to the
onset of diabetes (PD; n  8) and 2 wk (D2W; n  9), 3 mo (D3M; n  14), and 6 mo (D6M; n  10) post-onset of diabetes relative to lean Sprague-Dawley
controls (n 7). 2-KIC, 2-ketoisocaproic acid; 2-HB, 2-hydroxybutanoic acid. CIs are adjusted bootstrap percentile (BCa) intervals. *Values that are significantly
different (P  0.05) from lean Sprague-Dawley controls (Dunnett’s test).
E963ALTERED AMINO ACIDS AFTER INSULIN RESISTANCE ONSET
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00052.2016 • www.ajpendo.org
 by 10.220.32.246 on Novem
ber 8, 2017
http://ajpendo.physiology.org/
D
ow
nloaded from
 
rats compared with LC animals, and only UCD-T2DM rats
with diabetes of 6 mo duration (D6M) had increased circulat-
ing BCAA levels. Thus, the increase in BCAA at 6 mo
post-onset of diabetes occurs well after the UCD-T2DM rat
develops peripheral insulin resistance and progressive -cell
dysfunction (9). We interpret this to indicate that systemic
perturbations of BCAA metabolism are a consequence of
impaired metabolic regulation rather than a causative factor in
the progression of insulin resistance and diabetes in this model.
We utilized the UCD-T2DM rat model to assess changes in
plasma BCAA amino acids because the UCD-T2DM rat phe-
notype more closely resembles clinical T2DM in humans
compared with other rodent models. Although many features
of the UCD-T2DM rat model are consistent with the human
diabetic phenotype relative to other rodent models (e.g., func-
tional leptin signaling, female fertility, and later ages of dia-
betes onset), our results suggest divergent plasma BCAA
phenotypes. Higher BCAA concentrations are regularly ob-
served in individuals with insulin resistance or T2DM relative
to control groups in human clinical studies (12, 13, 29, 41, 45,
51, 52), leading some to hypothesize that elevated BCAAs
contribute or are causative of insulin resistance and/or deteri-
oration of metabolic health (30). This association is less con-
sistent in rodent models of insulin resistance and diabetes,
since it has been reported in some cases (10, 39, 40) but not in
others (19, 35). Results from the current study are more
consistent with the latter studies, and the increase in circulating
BCAA levels in the UCD-T2DM rat model appears to coincide
with late-stage fulminant diabetic phenotype rather than insulin
resistance. Thus, the BCAA metabolism in the UCD-T2DM rat
model and other rat models of diabetes may have limited direct
applicability to human T2DM. However, the results from this
model still provide important new evidence that elevations in
plasma BCAAs are not necessary to induce or further aggra-
vate insulin resistance.
Our observation of elevated plasma BCAAs coupled to the
reduction of most other plasma amino acids in unregulated
late-stage diabetes is not without precedent. Wijekoon et al.
(50) and Belabed et al. (5) observed similar plasma amino acid
trends in ZDF rats compared with age-matched lean counter-
parts. The elevation of plasma BCAAs, in contrast to all other
amino acids, supports the view that the BCAAs are differen-
tially regulated in the later stages of uncontrolled T2DM. This
would imply that the rate-limiting step in BCAA mitochondrial
metabolism, branched-chain ketoacid dehydrogenase complex
(BCKDC), may have a reduced enzymatic activity. It has long
been known that BCKDC is reduced during starvation and type
1 diabetes mellitus (17, 34), which, again, are conditions that
may be more reflective of the uncontrolled diabetes seen in
D3M and D6M rats herein. Teleologically, reduced BCKDC
activity under these conditions serves to attenuate irreversible
losses of these essential amino acids (34). Countering this
viewpoint, 2-ketoisocaproic acid, the branched-chain keto-acid
(BCKA) derivative of leucine, was relatively unchanged be-
tween the early and later stages of diabetes. A reduction in
BCKDC activity should increase plasma branched-chain keto-
Table 2. Fold difference of plasma amino acids and amino acid derivatives in diabetic UCD-T2DM rats relative to
prediabetic UCD-T2DM rats
Parameter D2W D3M D6M
Branched-chain amino acids and derivatives
Isoleucine 0.99 (0.85, 1.13) 1.10 (0.93, 1.28) 1.29 (1.08, 1.51)*
Leucine 0.96 (0.82, 1.09) 1.07 (0.91, 1.25) 1.24 (1.05, 1.43)*
Valine 1.02 (0.92, 1.14) 1.07 (0.93, 1.25) 1.30 (1.15, 1.53)*
2-KIC 0.99 (0.79, 1.32) 0.67 (0.49, 0.9)* 0.64 (0.51, 0.87)*
Gluconeogenic amino acids
Alanine 0.89 (0.75, 1.06) 0.69 (0.6, 0.78)* 0.66 (0.57, 0.77)*
Asparagine 0.98 (0.84, 1.15) 0.76 (0.66, 0.88)* 0.73 (0.61, 0.88)*
Aspartic acid 1.00 (0.89, 1.17) 0.94 (0.8, 1.12) 0.74 (0.59, 1.09)
Cysteine 1.21 (0.99, 1.63) 1.05 (0.84, 1.42) 0.75 (0.56, 1.14)
Glutamate 0.99 (0.81, 1.32) 0.76 (0.61, 0.97) 0.68 (0.54, 0.9)*
Glutamine 1.05 (0.92, 1.24) 0.81 (0.68, 0.97)* 0.69 (0.58, 0.82)*
Glycine 0.92 (0.82, 1.02) 0.78 (0.66, 0.92)* 0.59 (0.51, 0.65)*
Histidine 0.96 (0.76, 1.32) 0.81 (0.64, 1.12) 0.76 (0.6, 1.06)
Methionine 0.94 (0.83, 1.06) 0.81 (0.75, 0.9)* 0.82 (0.75, 0.95)*
Proline 0.49 (0.28, 0.97) 0.68 (0.41, 1.39) 0.79 (0.43, 1.47)
Serine 0.95 (0.82, 1.1) 0.68 (0.6, 0.77)* 0.6 (0.53, 0.7)*
Gluconeogenic and ketogenic amino acids
Phenylalanine 1.02 (0.92, 1.13) 0.87 (0.78, 0.98) 0.89 (0.8, 1.03)
Threonine 0.95 (0.83, 1.1) 0.60 (0.54, 0.66)* 0.61 (0.54, 0.69)*
Tryptophan 1.03 (0.9, 1.17) 0.78 (0.67, 0.93)* 0.63 (0.54, 0.72)*
Tyrosine 1.15 (0.95, 1.37) 1.04 (0.84, 1.25) 0.99 (0.82, 1.14)
Other amino acids and derivatives
Lysine 0.99 (0.82, 1.17) 0.83 (0.67, 1) 0.75 (0.59, 0.91)*
Arginine  ornithine 0.78 (0.54, 1.14) 0.56 (0.41, 0.78)* 0.65 (0.45, 0.97)*
Citrulline 1.13 (0.98, 1.39) 1.13 (0.98, 1.37) 1.12 (0.98, 1.33)
Ornithine 0.82 (0.62, 1.14) 0.60 (0.46, 0.83)* 0.68 (0.5, 0.94)*
2-HB 1.24 (1.06, 1.52)* 1.04 (0.92, 1.17) 1.05 (0.94, 1.2)
Data are mean fold difference (95% CI) of UCD-T2DM rats at 2 wk (D2W; n  9), 3 mo (D3M; n  14), and 6 mo (D6M; n  10) post-onset of diabetes
relative to prediabetic UCD-T2DM rats (n  8). 2-KIC, 2-ketoisocaproic acid; 2-HB, 2-hydroxybutanoic acid. CIs are adjusted bootstrap percentile (BCa)
intervals. *Values that are significantly different (P  0.05) from prediabetic UCD-T2DM rats (Dunnett’s test).
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acid concentrations; however, we suspect that significant re-
ductions in tissues containing high concentrations of branched-
chain aminotransferase (e.g., skeletal muscle and adipose tis-
sue) resulted in a diminution in the initial step in BCAA
catabolism. Although unavailable for the current study, infor-
mation regarding BCAA and amino acid enzyme activities
would be an important area for future studies in the UCD-
T2DM model.
The premise that blood BCAA patterns reflect metabolic
perturbations associated with T2D development or insulin
resistance suggests that amelioration of insulin resistance
through interventions would normalize BCAA concentrations.
Significant decreases in plasma BCAA concentrations have
been widely observed after gastric bypass surgery (25, 38, 43),
which is known to dramatically improve insulin sensitivity
within 6 days after surgery (49). Interestingly, Laferrère et al.
(25) compared individuals with equal weight loss from either
gastric bypass surgery or caloric restriction and found that only
the individuals treated with gastric bypass surgery had a
significant reduction in plasma BCAA concentrations. We
have found that baseline BCAA concentrations were signifi-
cantly correlated to HOMA-IR in obese women with metabolic
syndrome, but these correlations were no longer significant
after a weight loss intervention and improvements in insulin
Fig. 5. Variance in select plasma metabolites discriminates rats by diabetes status and progression. A: partial least squares-discriminant analysis (PLS-DA) scores
plot of lean Sprague-Dawley rats (LC; n  5) and UCD-T2DM rats before the onset (PD; n  6) of diabetes and 2 wk (D2W; n  7), 3 mo (D3M; n  10),
and 6 mo (D6M; n  7) post-onset of diabetes. Scores from individual rats are indicated as symbols. Confidence regions of group clusters are presented as 95%
confidence ellipses based on Hotelling’s T2 statistic. B: PLS-DA projections of discriminating metabolite factors in latent variables 1 and 2. Confidence ellipses
from A are overlayed to help distinguish metabolites associated with group clusters from the scores plot. Only metabolites that have structural identification were
annotated in the loadings plot for clarity. C: the log2 fold differences of UCD-T2DM rat groups relative to LC in metabolites selected in PLS-DA analyses are
presented as a heat map. Known and unknown metabolites are provided in the heat map; unknowns are indicated by their BinBase (BB) number.
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sensitivity (32). Pharmacological treatment of insulin resis-
tance or T2DM with thiazolidinedione (TZD) treatment de-
creased serum Val concentrations (4) and increased adipose
BCKDH gene expression (37). In contrast, Irving et al., found
no changes in plasma BCAA concentrations after 12-wk of
combined thiazolidinedione and metformin treatments (18).
Metformin treatment alone had no effect on plasma BCAA
(33) and increased plasma Leu and Iso after 2 days of treatment
(44). Collectively, these studies indicate that plasma BCAA
concentrations and BCAA pathways are linked to insulin
sensitivity, but these relationships are context specific. Future
studies in the UCD-T2DM rat that involve pharmacological
and nonpharmacologic interventions to normalize metabolic
homeostasis may help elucidate further the connections be-
tween systemic BCAAs and metabolic health.
A secondary aim of this study was to characterize more
globally which metabolic pathways best discriminate progres-
sion of T2DM-like phenotype in the UCD-T2DM rat model.
We found that most of the variance in the metabolome could be
explained by differences between either LC and early (PD and
D2W as a group) relative to later stages of diabetes (D3M and
D6M as a group), as highlighted in Figs. 5 and 6. Amino acids
(e.g., Thr, Ser, Ala, Gly, Gln, Trp, and Phe) and amino acid
derivatives were the most striking and abundant features in
both PLS-DA models and were associated with the early stages
of diabetes (i.e., greater in PD and D2W animals compared
with D3M and D6M animals). Two amino acid derivatives of
particular interest are 2-aminoadipic acid and aminomalonic
acid; both were reduced in the later stages of diabetes. Part of
the Lys synthesis pathway, 2-aminoadipic has been identified
in several metabolomics studies. Wang et al. (46) reported that
individuals from the Framingham Heart Study with the highest
concentrations of plasma 2-aminoadipic acid had a signifi-
cantly greater risk of later developing diabetes. Conversely,
oral supplementation of 2-aminoadipic acid in C56BL/6 male
mice fed a high-fat diet increased glucose clearance without
altering insulin secretion (46), suggesting an important role for
this metabolite in marking and modifying glucose disposal.
Aminomalonic acid has not been well-characterized in meta-
bolic disease, but has been isolated from Escherichia coli (7).
Although speculative, these results suggest an interaction be-
tween the metabolic health of the host and the microbiome, as
revealed previously in metabolomics studies in insulin-resis-
tant women (8). Future work will need to be done to identify
the origin of aminomalonic acid and its relationship to insulin
resistance. Considering the deterioration of glucose control that
defines progression from prediabetes to frank diabetes, it is not
surprising that several metabolites related to carbohydrate
metabolism were identified prominently in multivariate statis-
tical analyses discriminating early and late diabetes. Plasma
1,5-anhydroglucitol concentration is considered as a biomarker
for short-term glycemic control (27, 28, 41, 53). Renal reab-
sorption of 1,5-anhydroglucitol is inhibited under conditions of
hyperglycemia, thus explaining the lower plasma concentration
Table 3. Significantly different metabolites among LC and PD
Parameter LC PD FC P Value
BB307889 450 51 2,082  1163 2.210 0.01
BB225396 318 34 1,455  338 2.194 0.05
-Sitosterol 958 68 2,848  238 1.572 0.01
3-Phenyl-3-hydroxypropanoic acid 279 21 764  74 1.453 0.01
2,3-Dihydroxybutanoic acid 572 91 1,516  177 1.406 0.01
4-Hydroxyproline 3,397 254 8,804  1,075 1.374 0.05
Xylitol 2,679 241 5,953  688 1.152 0.05
BB199250 1,502 161 3,258  238 1.117 0.01
2-Deoxyerythritol 2,202 172 4,113  193 0.901 0.01
BB280602 179 19 319  26 0.834 0.05
Citric acid 51,760 4,875 82,715 3,460 0.676 0.05
BB199794 9,865 920 15,443  889 0.647 0.05
BB270003 1,123 137 1,753  127 0.642 0.05
BB232087 53,012 4,418 82,559 3,476 0.639 0.05
BB310006 374 26 579  48 0.631 0.05
BB433267 20,248 1,970 30,905 1,611 0.610 0.05
BB404568 925 70 1,355  79 0.551 0.05
Isothreonic acid 700 64 1,012  49 0.532 0.05
Indole-3-acetate 295 12 426  28 0.530 0.01
N-methylalanine 8,660 451 12,442  824 0.523 0.05
BB199777 50,042 3,656 71,849 3,438 0.522 0.05
BB318770 49,822 3,812 71,548 3,421 0.522 0.05
Threonine 62,697 2,290 85,811 2,652 0.453 0.01
Phosphoric acid 152,729 6,372 121,622 5,615 	0.329 0.05
Urea 495,391 4,4187 286,409 16,521 	0.790 0.05

-Ketoglutaric acid 3,766 391 2,059  175 	0.871 0.05
BB208647 2,964 260 1,384  91 	1.099 0.01
Monopalmitin-1-glyceride 371 26 172  24 	1.109 0.05
1, 5-anhydroglucitol 23,197 1,682 10,561 2,033 	1.135 0.05
Threonic acid 4,907 664 2,207  333 	1.153 0.05
1-Monostearin 1,993 364 142  10 	3.811 0.05
Values in LC and PD columns are means  SE. LC, lean Sprague-Dawley controls (n  7); PD, prediabetic UCD-T2DM rats (n  8); FC, log2 fold change
of PD relative to LC means; BB, BinBase. Unidentified metabolites indicated with their BB nomenclature. Units are quantifier ion peak heights from
time-of-flight/gas chromatography/mass spectrometry. Mann-Whitney U-tests were used to compare LC and PD groups. False discovery rate-adjusted P values
(Benjamini and Hochberg) are given.
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at the later stages of diabetes compared with prediabetes
stages. Higher glucuronic and hexuronic acids were associated
with later stages of diabetes. There is very little known about
how T2DM affects these metabolites, but plasma glucuronic
acid was also found to be increased in obese women with
T2DM relative to weight-matched control subjects (13).
Compared with lean Sprague-Dawley rats, prediabetic
UCD-T2DM rats have greater adiposity, are hyperphagic, are
insulin resistant, and display abnormal -cell morphology (9);
thus, it was not surprising to identify metabolites that differ-
entiate these animals. The groups of rats also shared housing
and dietary conditions and were of similar age, which were
strengths of the study design. However, we acknowledge that
comparing the UCD-T2DM rats with a lean Sprague-Dawley
strain introduces genetic strain differences that confound in-
terpretations specifically related to metabolic status. Neverthe-
less, further evaluations compared the within-strain transition
from prediabetes to frank diabetes, thus enabling a unique
opportunity to determine the metabolite landscape of diabetes
development in this model.
Untargeted metabolomics was used to determine temporal
differences in metabolites in a relatively small set of UCD-
Fig. 6. Variance in select plasma metabolites discriminates rats by diabetes status and progression when comparing only prediabetic with diabetic UCD-T2DM
rats. A: partial least squares-discriminant analysis (PLS-DA) scores plot characterization of UCD-T2DM rats before the onset (PD; n  6) of diabetes and 2 wk
(D2W; n  7), 3 mo (D3M; n  10), and 6 mo (D6M; n  7) post-onset of diabetes. PLS-DA projections of individual rats from latent variables 1 and 2 are
presented as symbols. Confidence regions of group clusters are presented as 95% confidence ellipses based on Hotelling’s T2 statistic. B: PLS-DA projections
of metabolites in latent variables 1 and 2 are presented as a loadings plot. Confidence ellipses from A are overlayed to help distinguish metabolites associated
with group clusters from the scores plot. Only metabolites that have structural identification were annotated in the loadings plot. C: the log2 fold differences of
UCD-T2DM rat groups relative to LC in metabolites selected in PLS-DA analyses are presented as a heat map. Known and unknown metabolites are provided
in the heat map; unknowns are indicated by their BinBase (BB) number.
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T2DM rats. Thus, a limitation of this study is that it involves
a high variable-to-sample ratio, which substantially increases
the chances of false discoveries. To counter this, we used a
PLS-DA modeling paradigm since it is robust to small sample
sizes and collinearity. We also used a training/test data scheme
to protect to validate PLS-DA models and minimize overfitting
(48). Our findings revealed that despite differences in some
metabolite patterns compared with human diabetes, there are
many plasma metabolites in the UCD-T2DM rat model that
have been identified previously in human cohorts. Therefore,
the UCD-T2DM rat may be an adequate model to validate and
explore mechanistic pathways associated with these potential
biomarkers of type 2 diabetes.
In conclusion, we utilized untargeted metabolomics to iden-
tify changes in plasma BCAAs and other amino acids during
the progression of uncontrolled diabetes in age-matched UCD-
T2DM rats. Plasma concentrations of BCAA did not increase
until 6 mo post-onset of diabetes and were inversely correlated
with adiposity and plasma insulin levels, suggesting that the
increases in BCAA are likely due to insulin deficiency and the
catabolic state of uncontrolled diabetes. In contrast to plasma
BCAAs, most non-BCAAs decreased during the progression of
diabetes. The increase in BCAAs relative to the decrease in
other amino acids in the later stages of diabetes is possibly
coupled to a negative feedback mechanism that limits BCAA
oxidation to mitigate protein losses. Multivariate analysis iden-
tified several other diabetes-regulated plasma metabolites that
included amino acids, amino acid derivatives, and carbohy-
drate derivatives. A clear alteration in circulating amino acids
was a dominant feature of diabetes progression in the UCD-
T2DM rat, highlighting that the metabolic dysregulation asso-
ciated with T2DM includes marked perturbations in circulating
amino acids. The late-stage plasma elevations of BCAAs
established that an increase in circulating BCAAs is not nec-
essary or sufficient to induce insulin resistance and diabetes in
the UCD-T2DM rat, and elevated BCAA levels were a conse-
quence, not a cause, of progressive metabolic deterioration.
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